# Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients

> **NCT00860600** · PHASE2 · COMPLETED · sponsor: **PhytoHealth Corporation** · enrollment: 14 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura (ITP)

## Interventions

- **DRUG:** PG2

## Key facts

- **NCT ID:** NCT00860600
- **Lead sponsor:** PhytoHealth Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00860600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00860600, "Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00860600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*